{"id":"W4380084938","doi":"10.1002/hon.3163_95","title":"GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (<i>R</i>/<i>R</i>) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Kite Pharma; F. Hoffmann-La Roche; Genentech; Celgene; Gilead Sciences; Pharmacyclics; Sanofi; Pfizer; Bristol-Myers Squibb","keywords":"Refractory (planetary science); Medicine; Lymphoma; Oncology; Internal medicine; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009010204,0.0004317646,0.0009886416,0.0002199358,0.0001658215,0.0006701496,0.0004123771,0.000397276,0.001003783],"category_scores_gemma":[0.0007291725,0.0002200341,0.0006833649,0.0003192133,0.0002169797,0.0005251792,0.0002397502,0.0009929239,0.0003147199],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006624802,"about_ca_system_score_gemma":0.0004517262,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004362001,"about_ca_topic_score_gemma":0.001595823,"domain_scores_codex":[0.9997485,0.0001103013,0.00002297893,0.00004442945,0.00003379224,0.00003994094],"domain_scores_gemma":[0.9995328,0.00008211133,0.0001678916,0.00004304761,0.00002790159,0.0001462821],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4746427,0.01013743,0.1368658,0.001323058,0.00300796,0.0008809454,0.0006795295,0.005144469,0.07063378,0.0002187825,0.007032433,0.2894332],"study_design_scores_gemma":[0.1283813,0.3847013,0.4515344,0.0002467367,0.002705544,0.002297858,0.0002893141,0.003767891,0.0107325,0.0003750537,0.01485221,0.0001159137],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949312,0.003255774,0.0001831809,0.0001625092,0.00002324532,0.0001638259,0.0004874041,0.00003557442,0.0007572419],"genre_scores_gemma":[0.9964716,0.001156664,0.0003575151,0.000226434,0.0000432936,0.0001253519,0.001223785,0.000008024159,0.000387342],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001003783,"threshold_uncertainty_score":0.004806638,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04688872729011315,"score_gpt":0.3771005735176207,"score_spread":0.3302118462275075,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}